A Randomized, Double‐Blind, Placebo‐Controlled, Twelve‐Week, Dose‐Ranging Study of Decernotinib, an Oral Selective JAK‐3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
2013 ◽
Vol 71
(Suppl 3)
◽
pp. 188.1-188
◽
2016 ◽
Vol 75
(Suppl 2)
◽
pp. 717.1-717